The FDA’s review also revealed delays in Philips’ internal investigations, with 54 inquiries failing to meet targeted completion dates—23 of which were delayed by more than 100 days
The quarter included three IPOs worth US$ 428 million and one Qualified Institutional Placement (QIP) worth US$ 88 million
The FW500 is designed to meet the evolving needs of mid-sized diagnostic laboratories
Sotyktu continues to demonstrate consistent efficacy and safety across rheumatic conditions
The antibody was designed and developed at Abzena’s Cambridge, UK,
Tourmaline is now an indirect wholly owned subsidiary of Novartis
The new CMC Process R&D Center represents a strategic investment in scale, sustainability, and specialization
It will produce a comprehensive range of dosage forms including tablets, hard gelatin capsules, liquids, injectables, topicals, and beta-lactam products
The event will be attended by 35,000+ industry professionals
Subscribe To Our Newsletter & Stay Updated
